Male osteoporosis: New insights in an understudied disease

Current Opinion in Rheumatology

Volumn 20, Issue 4, 2008, Pages 423-428

  Haney, Elizabeth M ^a,b   Bliziotes, M Michael ^a,c  

^a Department of Medicine ^*  (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Bone mineral ssdensity; Fracture; Men; Osteoporosis

Indexed keywords

ALENDRONIC ACID; LOOP DIURETIC AGENT; RISEDRONIC ACID; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; HIP FRACTURE; MORTALITY; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; ADULT; AGED; HUMAN; MALE; MIDDLE AGED;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS;

EID: 47049126489     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283025eb0     Document Type: Review

References (48)

1. NIH Consensus Development Panel on Osteoporosis Prevention D, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-795.
2. Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol Metab Clin N Am 2007; 36:399-419.
3. Nguyen ND, Ahlborg HG, Center JR, et al. Residual lifetime risk of fractures in women and men. J Bone Miner Res 2007; 22:781-788.
4. Bass E, French DD, Bradham DD, Rubenstein LZ. Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol 2007; 17:514-519.
5. Vestergaard P, Rejnmark L, Mosekilde L. Has mortality after a hip fracture increased? J Am Geriatr Soc 2007; 55:1720-1726. A population-based study of patients with hip fracture over 20 years in Denmark and controls without fracture. Mortality among those with hip fracture increased over the 20 years of the study compared with controls, who had declines in mortality.
6. Dennison E, Mohamed MA, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin N Am 2006; 32:617-629.
7. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23:279-302.
8. Wells JCK. Sexual dimorphism of body composition. Best Pract Res Clin Endocrinol Metab 2007; 21:415-430.
9. Lewis CE, Ewing SK, Taylor BC, et al. Predictors of nonspine fracture in elderly men: The MrOS Study. J Bone Miner Res 2007; 22:211-219. An analysis of risk factors for incident fracture among 5976 men age 65 years and older enrolled in MrOS, with average follow-up time of 4.1 years
10. Cauley JA, Fullman RL, Stone KS, et al. Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 2005; 16:1525-1537.
11. Marshall LM, Zmuda JM, Chan BKS, et al. Race and ethnic variation in proximal femur structure and BMD among older men. J Bone Miner Res 2008; 23: 121-130. A cross-sectional evaluation of MrOS qCT data to assess differences in femoral neck and shaft dimensions and volumetric BMD.
12. Eckstein F, Matsuura M, Kuhn V, et al. Sex differences of human trabecular bone microstructure in aging are site-dependent. J Bone Miner Res 2007; 22:817-824.
13. Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007; 297:387-394. A prospective study from the Dubbo Osteoporosis Epidemiology Study demonstrates similar rates of subsequent fracture in men and women with prior fracture.
14. Mackey DC, Lui L-Y, Cawthon PM, et al. High-trauma fractures and low bone mineral density in older women and men. JAMA 2007; 298:2381-2388. Data from MrOS and SOF shows significantly lower bone density among men and women with high trauma fracture than among those without fracture.
15. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281. A comprehensive review of vitamin D deficiency, including definition, treatment and assocations with other medical conditions.
16. Looker AC, Mussolino ME. Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res 2008; 23:143-150. An analysis of NHANES III data showing an association between 25(OH) -vitamin D levels and hip fracture among white non-Hispanic men and women age 65 and older.
17. Melton LJI, Orwoll ES, Wasnich RD. Does bone density predict fractures comparably in men and women? Osteoporos Int 2001; 12:707-709.
18. Cummings SR, Cawthon PM, Ensrud KE, et al. BMD and risk of hip and nonvertebral fractures in older men: A prospective study and comparison with older women. J Bone Miner Res 2006; 21:1550-1556.
19. Ferrar L, Jiang G, Cawthon PM, et al. Identification of vertebral fracture and nonosteoporotic short vertebral height in men: The MrOS Study. J Bone Miner Res 2007; 22:1434-1441.
20. Bauer DC, Ewing SK, Cauley JA, et al. Quantitative ultrasound predicts hip and nonspine fracture in men: The MrOS study. Osteoporos Int 2007; 18:771-777.
21. Mackey DC, Eby JG, Harris F, et al. Prediction of clinical nonspine fractures in older black and white men and women with volumetric BMD of the spine and areal BMD of the hip: The Health, Aging, and Body Composition Study. J Bone Miner Res 2007; 22:1862-1868.
22. Richards JB, Leslie WD, Joseph L, et al. Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res 2007; 22:228-234.
23. Siminoski K, Leslie WD, Frame H, et al. Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 2007; 10:120-4123.
24. Siris E, Delmas PD. Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application. Osteoporos Int 2008; 19:383-384.
25. Dawson-Hughes B, Tosteson ANA, Melton LJI, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008; 19:449-458. Examination of the WHO fracture risk tool as it pertains to US populations.
26. NOF. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008. New guidelines from NOF using the WHO risk factor assessment tool for calculation of 10-year absolute fracture risk. Includes guidance for clinicians on how to make treatment decisions based on the facture risk calculation.
27. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 188:1033-1046. A series of meta-analyses using nine primary cohorts and 11 validation cohorts to assess risk factors. This work forms the basis for the WHO risk prediction tool and the new WHO guideline.
28. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343:604-610.
29. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004; 24:110-113.
30. Gonnelli S, Cepollaro C, Montagnini A, et al. Alendronate treatment in men with primary osteoporosis: A three-year longitudinal study. Calcif Tissue Int 2003; 73:133-139.
31. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study. J Clin Endocrinol Metab 2001; 86:5252-5255.
32. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799-1809. A randomized controlled trial (RCT) of zoledronic acid in men and women following hip fracture. The treatment group showed reduced new fracture rates and improved mortality compared with placebo.
33. Abrahamsen B, Nielsen MF, Eskildsen P, et al. Fracture risk in Danish men with prostate cancer: A nationwide register study. BJU Int 2007; 100:749-754.
34. Ryan CW, Huo D, Bylow K, et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int 2007; 100:70-75.
35. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028-2039. An 18-month RCT comparing teriparatide with alendronate in men and women aged 22-89 with a history of 3 months of glucocorticoid use. The incidence of nonvertebral fractures was equivalent for the two groups at 12 months; there were fewer new vertebral fractures in the teriparatide group. Men and women responded equally to treatment.
36. Tracz MJ, Sideras K, Bolona ER, et al. Clinical review: Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006; 91: 2011-2016.
37. Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab 2001; 86:2020-2026.
38. Hall GM Jr, Larbre JP, Spector TD, et al. A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol 1996; 35:568-573.
39. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89:503-510.
40. Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol 2001; 56A:M266-M272.
41. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156:1173-1177.
42. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966-1972.
43. Gao W, Dalton JP. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today 2007; 12 (5/6):241-248.
44. Miner JN, Chang W, Chapman MS, et al. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology 2007; 148:363-373.
45. Kiel DP, Magaziner J, Zimmerman S, et al. Efficacy of a hip protector to prevent hip fracture in nursing home residents: The HIP PRO randomized controlled trial. JAMA 2007; 298:413-422. A meta-analysis of RCTs of calcium or calcium plus vitamin D for prevention of fracture.
46. Tang BMP, Eslick GD, Nowson C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370:657-666.
47. Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of Randomized Controlled Trials. J Clin Endocrinol Metab 2007; 92:1415-1423. A meta-analysis of RCTs of vitamin D with or without calcium for prevention of fracture.
48. Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007; 298:629-637. A Markov model simulation of cost-effectiveness of screening and treatment for osteoporosis in older men.